Compare Dyne Therapeutics Inc. Common Stock (DYN) vs iShares MSCI South Africa ETF (EZA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs iShares MSCI South Africa ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while iShares MSCI South Africa ETF trades at $63.18 (market cap $465.74M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 6.1× iShares MSCI South Africa ETF's market cap, and iShares MSCI South Africa ETF is more actively traded (245,187 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and iShares MSCI South Africa ETF for 73 Days on average.
| DYN | EZA | |
|---|---|---|
Market Cap | $2.86B | $465.74M |
Volume | 3,341,579 | 245,187 |
Sector | Health | Broad Market / Factor |
52-Week High | $26.78 | $81.60 |
52-Week Low | $14.60 | $60.43 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EZA trades at $64.32, up 0.86% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF, which tracks South African equities, faces headwinds from global reflation and higher capital costs impacting its financial and commodity-heavy holdings. Recent news highlighted a brief move above the 50-day average, but macro concerns dominate the narrative.
The outlook remains cautious due to exposure to volatile sectors like gold and banking amid rising rates. Investment opportunity hinges on South Africa's economic stability, but risks include commodity price pressures and unfavorable yield dynamics. Investor sentiment is neutral to bearish, with technicals suggesting near-term resistance at $64.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →
